Top 10 Leading Companies in the South Korea Amlodipine Besylate Market | Company list 2026

South Korea Amlodipine Besylate Market Overview

According to 6wresearch, the South Korea Amlodipine Besylate Market is growing, and the major factor contributing to this growth is the increasing number of people suffering from hypertension and other heart problems, aggravated by a rapidly aging population. Amlodipine Besylate is a calcium channel blocker and is used for the treatment of high blood pressure and angina.

The rising preference for effective and cost-efficient treatment for these problems and the growing demand for generic drugs are the major factors for the growth of the market. Additionally, the demand for the preferred drugs is expanding because of the presence of major players in the market and the rising adoption of fixed-dose combination therapies that integrate Amlodipine with other cardiovascular agents.

Competitive Landscape

The competitive landscape of the South Korea Amlodipine Besylate industry is characterized by the dominance of several multinational corporations and local pharmaceutical companies. The major players use their vast distribution network and strong production capabilities to maintain their competitive streak in the market. Research and development are another important factor in this market as companies seek to develop cost-effective products in the market, particularly focusing on S-enantiomer formulations and novel combinations to improve efficiency and reduce side effects.

Below is a list of leading players operating in the South Korea Amlodipine Besylate Market:

1. Pfizer Korea

Pfizer is a major player in providing the original Amlodipine Besylate, which remains a gold standard for treating hypertension and angina.

2. Hanmi Pharm Co., Ltd.

Hanmi is a leader in the domestic market, known for combining Amlodipine with other agents to provide high-efficacy hypertension control.

3. Daewoong Pharmaceutical Co., Ltd.

Daewoong maintains a high share through robust distribution network for its diverse portfolio of cardiovascular and metabolic disease treatments.

4. Chong Kun Dang Pharmaceutical Corp.

Chong Kun Dang offers a wide array of affordable and high-quality cardiovascular drugs, utilizing advanced synthesis technology to produce reliable Amlodipine formulations.

5. Boryung Pharmaceutical Co., Ltd.

Boryung is a pioneer in blood pressure management through its Dukarb line, which integrates Amlodipine with Fimasartan for superior clinical outcomes.

6. HK inno. N Corporation

HK inno. N specializes in high-quality generic and innovative respiratory and cardiovascular health products, ensuring competitive treatment options.

7. Yuhan Corporation

Yuhan is recognized for its high-quality cardiovascular medications and strategic partnerships, frequently providing essential antihypertensive treatments.

8. JW Pharmaceutical

JW Pharmaceutical provides a diverse range that focuses on fixed-dose combinations that improve patient compliance for chronic hypertension management.

9. Dong-A ST Co., Ltd.

Dong-A ST is a leading provider of advanced generics and ethical drugs, focusing on cost-effective cardiovascular treatments.

10. Samjin Pharmaceutical Co., Ltd.

Samjin produces a variety of essential cardiovascular medicines, like antiplatelet and antihypertensive agents used in long-term heart health management.